DRI-C21041 DIEA is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 DIEA inhibits the immune response induced by alloantigen.
DRI-C21041 DIEA inhibits CD40L-induced B-cell activation, proliferation, and the activation of NF-κB[1].
References:
[1]. Lu H, et, al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5(1):213.
















